Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $84,350.43 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 3,243 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the transaction, the insider owned 32,316 shares of the company’s stock, valued at $840,539.16. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $26.21 on Monday. Maze Therapeutics, Inc. has a 12 month low of $14.27 and a 12 month high of $53.65. The stock has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The stock’s fifty day moving average price is $28.69 and its 200-day moving average price is $31.06. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, equities analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MAZE. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the second quarter valued at approximately $122,983,582. Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the 2nd quarter worth $41,435,000. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics in the second quarter worth $133,502,907. Spruce Street Capital LP bought a new stake in shares of Maze Therapeutics in the first quarter worth $5,970,000. Finally, Hhlr Advisors LTD. purchased a new stake in Maze Therapeutics during the second quarter valued at $10,922,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. BTIG Research restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $66.00.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.